161 related articles for article (PubMed ID: 36917303)
1. Implications for surveillance for breast cancer patients based on the internally and externally validated BRENDA-metastatic recurrence score.
Ebner F; Salmen J; Dayan D; Kiesel M; Wolters R; Janni W; Wöckel A; Wischnewsky M
Breast Cancer Res Treat; 2023 May; 199(1):173-184. PubMed ID: 36917303
[TBL] [Abstract][Full Text] [Related]
2. BRENDA-Score, a Highly Significant, Internally and Externally Validated Prognostic Marker for Metastatic Recurrence: Analysis of 10,449 Primary Breast Cancer Patients.
Wischnewsky M; Schwentner L; Diessner JD; De Gregorio A; Joukhadar R; Davut D; Salmen J; Bekes I; Kiesel M; Müller-Reiter M; Blettner M; Wolters R; Janni W; Kreienberg R; Wöckel A; Ebner F
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34206581
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer.
Diessner J; Wischnewsky M; Stüber T; Stein R; Krockenberger M; Häusler S; Janni W; Kreienberg R; Blettner M; Schwentner L; Wöckel A; Bartmann C
BMC Cancer; 2016 May; 16():307. PubMed ID: 27175930
[TBL] [Abstract][Full Text] [Related]
4. Independent Validation of the BRENDA-Score Breast Cancer Prognosis Prediction Tool In Chinese Patients.
Ma S; Liu Y; Gao P; Ma R
Clin Breast Cancer; 2024 Jul; 24(5):e389-e395. PubMed ID: 38538518
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of the AJCC 8th edition staging system for selecting patients with T1-2N1 breast cancer for post-mastectomy radiotherapy: a joint analysis of 1986 patients from two institutions.
Wang S; Wen G; Tang Y; Yang Y; Jing H; Wang J; Zhang J; Zhao X; Sun G; Jin J; Song Y; Liu Y; Fang H; Zhang Y; Li Y
BMC Cancer; 2020 Aug; 20(1):792. PubMed ID: 32838753
[TBL] [Abstract][Full Text] [Related]
6. Outcome analysis of primary breast cancer patients who declined adjuvant chemotherapy-results from the prospective multi-center BRENDA II study.
Leinert E; Schwentner L; Janni W; Wöckel A; Herbert SL; Herr D; Kühn T; Flock F; Felberbaum R; Kreienberg R; Fink V; Dayan D; Ernst K; Singer S;
Breast Cancer; 2022 May; 29(3):429-436. PubMed ID: 35178667
[TBL] [Abstract][Full Text] [Related]
7. Prediction of outcome of patients with metastatic breast cancer: evaluation with prognostic factors and Nottingham prognostic index.
Liu MT; Huang WT; Wang AY; Huang CC; Huang CY; Chang TH; Pi CP; Yang HH
Support Care Cancer; 2010 Dec; 18(12):1553-64. PubMed ID: 19904562
[TBL] [Abstract][Full Text] [Related]
8. An internally and externally validated prognostic score for metastatic breast cancer: analysis of 2269 patients.
Regierer AC; Wolters R; Ufen MP; Weigel A; Novopashenny I; Köhne CH; Samonigg H; Eucker J; Possinger K; Wischnewsky MB
Ann Oncol; 2014 Mar; 25(3):633-638. PubMed ID: 24368402
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Ohnstad HO; Borgen E; Falk RS; Lien TG; Aaserud M; Sveli MAT; Kyte JA; Kristensen VN; Geitvik GA; Schlichting E; Wist EA; Sørlie T; Russnes HG; Naume B
Breast Cancer Res; 2017 Nov; 19(1):120. PubMed ID: 29137653
[TBL] [Abstract][Full Text] [Related]
10. Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients.
Bakre MM; Ramkumar C; Attuluri AK; Basavaraj C; Prakash C; Buturovic L; Madhav L; Naidu N; R P; Somashekhar SP; Gupta S; Doval DC; Pegram MD
Cancer Med; 2019 Apr; 8(4):1755-1764. PubMed ID: 30848103
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
Sanpaolo P; Barbieri V; Genovesi D
Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study.
Stavridi F; Kalogeras KT; Pliarchopoulou K; Wirtz RM; Alexopoulou Z; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Koutras A; Lazaridis G; Christodoulou C; Pentheroudakis G; Laskarakis A; Arapantoni-Dadioti P; Batistatou A; Sotiropoulou M; Aravantinos G; Papakostas P; Kosmidis P; Pectasides D; Fountzilas G
PLoS One; 2016; 11(10):e0164013. PubMed ID: 27695115
[TBL] [Abstract][Full Text] [Related]
13. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
14. Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer.
Dieci MV; Conte P; Bisagni G; Bartolini S; Frassoldati A; Generali D; Piacentini F; Griguolo G; Tagliafico E; Brasó Maristany F; Chic N; Paré L; Miglietta F; Vicini R; D'Amico R; Balduzzi S; Prat A; Guarneri V
J Natl Cancer Inst; 2024 Jan; 116(1):69-80. PubMed ID: 37676829
[TBL] [Abstract][Full Text] [Related]
15. Metastatic relapse of stage I-III breast cancer in New Zealand.
Lao C; Kuper-Hommel M; Elwood M; Campbell I; Lawrenson R
Cancer Causes Control; 2021 Jul; 32(7):753-761. PubMed ID: 33830387
[TBL] [Abstract][Full Text] [Related]
16. Local-regional breast cancer recurrence: prognostic groups based on patterns of failure.
Moran MS; Haffty BG
Breast J; 2002; 8(2):81-7. PubMed ID: 11896752
[TBL] [Abstract][Full Text] [Related]
17. Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer: clinical utility of the CPS + EG score.
Michel LL; Sommer L; González Silos R; Lorenzo Bermejo J; von Au A; Seitz J; Hennigs A; Smetanay K; Golatta M; Heil J; Schütz F; Sohn C; Schneeweiss A; Marmé F
Breast Cancer Res Treat; 2019 Sep; 177(2):437-446. PubMed ID: 31236813
[TBL] [Abstract][Full Text] [Related]
18. PPFIA1 is upregulated in liver metastasis of breast cancer and is a potential poor prognostic indicator of metastatic relapse.
Yang J; Wu NN; Huang DJ; Luo YC; Huang JZ; He HY; Lu HL; Song WL
Tumour Biol; 2017 Jul; 39(7):1010428317713492. PubMed ID: 28720060
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors.
Lynch SM; Russell NM; Barron S; Wang CA; Loughman T; Dynoodt P; Fender B; Lopez-Ruiz C; O'Grady A; Sheehan KM; Fay J; Amberger-Murphy V; Saha A; Klinger R; Gonzalez CA; Al-Attar N; Rahman A; O'Leary D; Lanigan FT; Bracken AP; Crown J; Kelly CM; O'Connor DP; Gallagher WM
Eur J Cancer; 2021 Jul; 152():78-89. PubMed ID: 34090143
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of Site-Specific Metastases and Surgery in De Novo Stage IV Triple-Negative Breast Cancer: A Population-Based Analysis.
Gu Y; Wu G; Zou X; Huang P; Yi L
Med Sci Monit; 2020 Feb; 26():e920432. PubMed ID: 32043484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
